Anika Therapeutics, Inc. (ANIK) Stock

Anika Therapeutics, Inc. (ANIK) is a Healthcare stock trading at $21.39 (as of 2026-08-20), with a market capitalization of $286.26M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Anika Therapeutics, Inc. develops, manufactures, and commercializes products based on a hyaluronic acid technology platform for early intervention orthopedic care. Its osteoarthritis pain management products include Monovisc, Orthovisc, Cingal, and Hyvisc, along with joint preservation, soft-tissue repair, regenerative and other HA-based applications, sold in the United States, Europe, and internationally.

Understand Anika Therapeutics, Inc.: how it makes money

Anika Therapeutics develops, manufactures, and commercializes hyaluronic-acid based orthopedic products for osteoarthritis pain management and joint preservation and restoration, including Monovisc, Orthovisc, Cingal, and Hyvisc, and sells these products commercially and through channels such as OEM and international markets.

Its profit model is tied to adoption of its hyaluronic-acid orthopedic technologies by clinicians, which drives sales of its osteoarthritis pain management and joint preservation and restoration product families.

Revenue by segment (latest quarter)
OA Pain$0.0B
Joint Preservation$0.0B

Business quality (Weak): The business focus and product categories are clear, but the provided data links only some revenue lines to operating activity, and the latest-quarter financial and segment figures are very small, which can make trends harder to interpret.

Bull case

  • Strong gross profitability in the latest quarter: Gross margin was 64.2% for the period ended 2026-03-31.
  • Active expansion of the Integrity implant ecosystem: Operationally, the company reported 3,000 Integrity Implant System Cases Completed and 300 Integrity Surgeon Users.

Bear case

  • Operating losses in the latest quarter: Operating margin was -18.5% for the period ended 2026-03-31.
  • Business scale appears limited in the provided quarter snapshot: Revenue from continuing operations is shown as 0.03 USD_B, which means a small absolute revenue base can amplify the impact of operating expense changes.
Valuation — source: SEC EDGAR (first-party)
Price$21.39
Market Cap$286.26M
Price / Book2.09
Price / Sales2.39
FCF Yield-7.2%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$112.82M
Net Margin-9.6%
Revenue Growth (YoY)-5.9%
EPS Growth (YoY)-80.2%
FCF Growth (YoY)-287.1%
Financial Health — source: SEC EDGAR
Altman Z-Score5.04 (safe)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Medical Equipment)32.9
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock Fund Advisors ($57.46M)
Institutional Holders Tracked10
Congressional Trades (recent)8
Company
SectorHealthcare
IndustryMedical Equipment
CEOStephen D. Griffin
Employees288
CountryUS
IPO Date1993-05-03

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Orchestra BioMed Holdings, Inc. (OBIO)
  • TriSalus Life Sciences, Inc. (TLSI)
  • AVITA Medical, Inc. (RCEL)
  • Embecta Corp. (EMBC)
  • Treace Medical Concepts, Inc. (TMCI)
  • OraSure Technologies, Inc. (OSUR)
  • InfuSystem Holdings, Inc. (INFU)
  • Neuronetics, Inc. (STIM)
ANIK earnings history · ANIK institutional & insider holders · ANIK KPIs & operating metrics · ANIK financials · ANIK investor presentations & press releases · ANIK SEC filings · ANIK peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.